Dallas, Texas 04/17/2014 (FINANCIALSTRENDS) – EXACT Sciences Corporation (NASDAQ:EXAS) is the molecular diagnostics which will focus on the detection as well as prevention of colorectal cancer.
EXACT Sciences Corporation (NASDAQ:EXAS) will now offer non-invasive as well as stool-based DNA, sDNA has supported screening test as well as designed to DNA markers to detect the blood content in stools. The antibody-fecalimmunochemical test FIT, has been designed to investigate pre-cancer lesions as well as polyps, across the different colorectal cancer stages.
EXACT Sciences Corporation (NASDAQ:EXAS) is being seen as an overvalued assumption which also has PMA approval. Since industry indicators have found that there is a major need for colon cancer treatment, the lifetime risk is likely to be that much higher, which is currently at 5%, where the benefits are in the form of colon cancer as well as screening market.
EXACT Sciences Corporation (NASDAQ:EXAS) in developing its products has been working within the case limits of the American Cancer Society. According to available statistics, “96,830 new cases of colon cancer and 40,000 new cases of rectal cancer are expected in 2014. Colorectal cancer is expected to cause about 50,310 deaths during 2014.”
One of the key products for EXACT is Cologuard
EXACT Sciences Corporation (NASDAQ:EXAS) has been working on a range of solutions for this condition. One of the most accurate standards used to detect colon cancer is the Gold Standard – Colonoscopy. These are considered to be one of the screening methods which besides being invasive colonoscopy and are in line with sigmoidoscopy.
It is also used to detect Fecal occult Blood Test, which is a non-invasive test. It checks for blood within the fecalmaterial, by the method of detecting haemoglobin protein stool samples as well as main direct competitors which belong to Cologuard. It demonstrates 92% sensitivity or true positive rate and is typically used in finding out and discovering different types of cancer.